FAQs
Important Safety Information
Prescribing Information
Patient Medication Guide
Infusion Center Locator
E-Sign TOUCH
®
Enrollment Form
Patient Site
Important Safety Info
Prescribing Information
E-Sign TOUCH
®
Enrollment Form
Patient Site
Toggle navigation
Start TYSABRI
Risk of Relapsing MS
Dosing & Administration
Coverage & Reimbursement
QuickStart
Infusion Center Locator
Biogen Support Services
Efficacy & Safety
Pivotal Trial
PML Risk
Adverse Reactions
Onset of Efficacy
Patient Experience & Data
Real-World Experience
10-Year Safety & Efficacy Results
Global Safety Study
NEDA Study
HR/Neuro QoL
Peer Perspectives
Proposed MOA & PK/PD
Proposed MOA
Effect on Lymphocyte Counts
Pharmacokinetics
TOUCH® Prescribing Program
TOUCH On-Line
iAssist®
Register/
Sign In
My Account
Edit
Profile
Log Out
FAQs
Important Safety Information
Prescribing Information
Patient Medication Guide
Infusion Center Locator
E-Sign TOUCH
®
Enrollment Form
Patient Site
Proposed MOA
Effect on Lymphocyte Counts
Pharmacokinetics
CONSIDER PHARMACOKINETICS
OF TYSABRI
1
Half-life (mean ± SD): 11 ± 4 days
Volume of distribution (mean ± SD): 5.7 ± 1.9 L
Clearance (mean ± SD): 16 ± 5 mL/hour
Time to steady-state: ~24 weeks after every 4 weeks of dosing
NEXT: TOUCH
®
On-Line